Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
178.11
-0.79 (-0.44%)
Apr 10, 2026, 4:00 PM EDT - Market closed
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts that cover Axsome Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $211.12, which forecasts a 18.53% increase in the stock price over the next year. The lowest target is $162 and the highest is $260.
Price Target: $211.12 (+18.53%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 7 | 7 | 7 |
| Buy | 11 | 11 | 11 | 10 | 9 | 9 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 21 | 18 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $251 → $259 | Strong Buy | Maintains | $251 → $259 | +45.42% | Apr 10, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $220 → $245 | Strong Buy | Maintains | $220 → $245 | +37.56% | Mar 25, 2026 |
| UBS | UBS | Strong Buy Maintains $248 → $251 | Strong Buy | Maintains | $248 → $251 | +40.92% | Feb 24, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $205 → $220 | Strong Buy | Maintains | $205 → $220 | +23.52% | Feb 24, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $219 → $222 | Buy | Maintains | $219 → $222 | +24.64% | Feb 24, 2026 |
Financial Forecast
Revenue This Year
1.01B
from 638.50M
Increased by 58.18%
Revenue Next Year
1.57B
from 1.01B
Increased by 55.45%
EPS This Year
-0.70
from -3.68
EPS Next Year
6.64
from -0.70
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.1B | 1.9B | |||
| Avg | 1.0B | 1.6B | |||
| Low | 890.7M | 1.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 73.8% | 91.3% | |||
| Avg | 58.2% | 55.4% | |||
| Low | 39.5% | 19.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.31 | 12.46 | |||
| Avg | -0.70 | 6.64 | |||
| Low | -2.14 | 1.85 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.